A number of independent lines of evidence converge indicating a role for nitric oxide (NO) in angiogenesis. Our data support the existence of an autocrine loop exerted by microvascular endothelium in angiogenesis which involves NO production, cyclic GMP elevation and fibroblast growth factor-2 (FGF-2) expression. Our results indicate that NO production significantly contributes to the growth-promoting effect of vasodilating peptides and vascular endothelial growth factor (VEGF), but not for that of FGF-2. On these basis, the nitric oxide pathway appears to be a promising target to be considered in pro-and anti-angiogenic therapeutic strategies.
Background
The occurrence of neovascularization in the articular cartilage represents a major problem in the evolution of the inflammatory process affecting joints. Therapeutic intervention in rheumatological diseases as well as for other angiogenesis dependent diseases is thus the block of pathological angiogenesis. The comprehension of the mechanism underlying the angiogenesis process and the characterization of the molecules involved, is instrumental for the development of antiangiogenic strategies.
In order to study angiogenesis we have focused our effort in monitoring the vascularization process occurring in avascular tissue, i.e., the cornea of albino rabbits. The cornea assay respect to the other in-vivo assays, has the advantage of measuring only new blood vessels, since the cornea is initially avascular.
The steps required for new vessel growth are biologically complex and require co-ordinate regulation of contributing components, including modifications of cell-cell interactions, proliferation and migration of endothelial cells and matrix degradation involving urokinase-type plasminogen activator (uPA). 1 The observation that in-vivo angiogenesis is accompanied by vasodilation and that many angiogenesis effectors possess vasodilating properties, prompted us to search for evidence of a molecular/ biochemical link between vasodilation and angiogenesis. Indeed both events occur under a strict control exerted by the endothelial cells on the surrounding cellular components.
Endothelium-dependent relaxation is known to arise from endothelium derived nitric oxide (NO) inducing cyclic GMP (cGMP) in the vascular smooth muscle cell. 2 The synthesis of NO by endothelial cells can be blocked by L-arginine analogs such as Nw-mono-methyl-L-arginine (L-NMMA) and Lw-nitro-L-arginine methyl ester (L-NAME), while D-isomers are ineffective.
Three experimental observations attracted our attention to study the role of NO in angiogenesis. First, in experimental models where angiogenesis can be directly monitored, vasodilation and hyperemia of the pre-existing capillaries and the persistence of a dilation state of the newly formed vessels are typical findings. 3 Second, several angiogenesis factors/mediators promote relaxation in vascular preparations and peptides known to induced endothelium-mediated vasorelaxation are angiogenic. 4, 5 Third, persistent vasodilation is a specific feature in tumor vasculature and in the surrounding tissue. Furthermore in studying endothelium dependent vasodilating peptides we demonstrated a role for NO in angiogenesis.
Results

THE NO/CGMP PATHWAY IN ANGIOGENESIS
Several reports have implicated a role for NO synthase in angiogenesis. For example, it was shown that angiogenic activity was only released from bacterial endotoxin treated human monocytes in the presence of L-arginine. 6 More recently the role of NO in mediating the angiogenic activity elicited by different cytokines has been described. 7 Similarly L-Arginine was shown to favour healing and angiogenesis in gastric ulcerations while NO synthase inhibitors delayed it. 8 To assess the role of NO in angiogenesis we investigated whether NO could act as an angiogenesis effector per se and as a modulator of the activity and/or the production of angiogenesis factors. The relevance of NO in angiogenesis was assessed in vitro by testing the activity of NO producing agents on the cellular events of angiogenesis in cultured capillary endothelium, and in vivo in rabbit corneas receiving angiogenesis effector and tumor cell implant during systemic treatment with NO-synthase inhibitors.
Following this approach we could demonstrate that chemical mediators which activate the constitutive NO synthase, like substance P (SP) as well as NO donors, such as sodium nitroprusside (NaNP), promoted endothelial cell proliferation and migration in vivo and in vitro, while inhibitors of NO synthase suppressed these responses. 9 The growth promoting effect of NO appeared to be linked to cGMP generation in cultured endothelium, 10 suggesting the existence of an autocrine/paracrine loop in NO effect. In vivo, NO synthase inhibitors suppress angiogenesis induced by vasodilating effectors like SP and prostaglandin E 1 (PGE 1 ) but did not affect angiogenesis induced by fibroblast growth factor-2 (FGF-2). 9 
THE MECHANISM UNDERLYING NO-INDUCED ANGIOGENESIS
INVOLVES ENDOGENOUS FGF-2 PRODUCTION
The mechanism by which NO controls angiogenesis was not completely clarified. A possible explanation was that NO could modulate the activity and/or the production of angiogenesis factors as indicated for other peptides. 11 Fibroblast growth factor-2 (FGF-2) is a potent angiogenesis factor and in vitro studies have demonstrated that FGF-2 can initiate the cellular responses associated with angiogenesis including uPA production and cell division in autocrine fashion. 1, 12 In order to elucidate the mechanism of action of NO in angiogenesis, we investigated the interaction of NO and FGF-2 in signalling proliferation and uPA production in vascular endothelium. In postcapillary venular endothelial cells we found that dose-dependent increase in uPA activity paralleled DNA synthesis in response to FGF-2 and to the NO-donor drug NaNP. Neutralizing anti-FGF-2 antibodies blocked uPA production and DNA synthesis following nipride treatment. Similar results were obtained when increase in NO levels were produced by the use of SP. Endothelial cells exhibited increased expression of mRNA and protein of FGF-2 and the proliferation induced by SP was blocked by anti-FGF-2 antibodies and by NO synthase inhibitors. Thus NO, both exogenous and endogenous, induced the endothelial cells to produce FGF-2 and to respond to the endogenous growth factor revealing a feedback loop between vasodilation and angiogenesis controlled by the endothelium via NO and FGF-2. 13 
VEGF, NO AND ANGIOGENESIS
To then assess the role of NO in tumor angiogenesis we investigated whether the L-arginine/NO pathway participated to vascular endothelial growth factor (VEGF) and FGF-2 activity. VEGF is a secreted endothelial-specific growth factor that is strongly angiogenic in vivo. 14 Moreover, VEGF effects on permeability and vascular tone are coupled to nitric oxide production. 15 We started by investigating whether the NO pathway participated in VEGF activity. We found that NO production significantly contributed to the growth-promoting effect of VEGF, but not for that of FGF-2. 16 Postcapillary endothelial cell mobilization, adhesion and growth induced by VEGF were blocked by the NO synthase inhibitor L-NMMA and by the guanylate cyclase inhibitor LY 83583, while these inhibitors did not modify FGF-2 effects. VEGF effect appears to be selectively linked to the NO pathway. In fact, L-NAME, but not D-NAME, completely blocked neovascularization induced by the VEGF transfectants, while the cells remained dormant in the cornea. Consistently, VEGF induced angiogenesis was inhibited by NO synthase inhibitors while the angiogenic activity of FGF-2 was not affected. Thus, nitric oxide appeared to be a downstream imperative of VEGF but not FGF-2 induced angiogenesis. 17 
Conclusions
In microvascular endothelium, NO production significantly contributes for the growth-promoting effect of vasodilating peptides and VEGF, but not for that of FGF-2. The specificity of the NO synthase inhibitors on VEGF induced angiogenesis and not FGF-2 induced angiogenesis provides new evidence for the existence of the two angiogenic pathways. Thus, although the NO pathway integrates several chemical and physical modulators of the angiogenic process, not all angiogenic factors depend on this signalling cascade. This highlights the problem that arises as a result of the fact that angiogenesis involves multiple factors, namely, that blocking of any single angiogenic factor is unlikely to be an effective antiangiogenic strategy. More work with specific inhibitors of the NO synthase isoforms is needed nevertheless the nitric oxide pathway stays as a promising target for consideration in anti-angiogenic therapeutical strategies.
